BEPACT- Lung: Impact of Patient Characteristics on Pneumo-oncologists Non Small Cell Lung Cancer (NSCLC) Systemic Treatment Decision in Belgium

Study Overview
=================
Brief Summary
-----------------
The treatment landscape of metastatic non small cell lung cancer (NSCLC) is rapidly evolving. There are new diagnostic and treatment options available in the coming months and years. New combination treatments will give different solutions to pneumo-oncologists who might be guided by certain patient and tumor characteristics. The link between patient and tumor characteristics in untreated stage IV non small cell lung cancer (NSCLC) patients and systemic treatment needs further investigation, allowing the identification of possible treatment issues, data gaps and/or areas of improvement.

Detailed Description
-----------------
This is a multicenter, non-interventional, cross-sectional study. Consecutive patients with metastatic stage IV non small cell lung cancer (NSCLC) selected for systemic treatment or best supportive care will be included in the trial at the time the patient signed the informed consent form (ICF). Patients that were selected for systemic treatment, should have received at least their first dose and a maximum of one cycle of the same treatment. The pneumo-oncologist that treats the patient will fill in the CRF, indicating the systemic treatment option and the link with the variable categories that impacted the choice for a systemic treatment option.

Official Title
-----------------
BEPACT Lung: Impact of Patient Characteristics on Pneumo-oncologists Non Small Cell Lung Cancer (NSCLC) Systemic Treatment Decision in Belgium: A Cross-sectional Study

Conditions
-----------------
Stage IV Non-small Cell Lung Cancer

Intervention / Treatment
-----------------
* Other: None - Common practice


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Have voluntarily agreed to participate by giving written informed consent/assent for the trial. Have a histologically or cytologically confirmed diagnosis of stage IV non-small cell lung cancer (NSCLC) on first-line (1L) systemic treatment. Have received at least their first dose of the selected systemic treatment and a maximum of 1 cycle of the same treatment. Patients that were selected to receive best supportive care will not have to comply to this inclusion criterion. Be ≥ 18 years of age on day of signing informed consent. Exclusion Criteria: Has received prior systemic treatment for their metastatic non-small cell lung cancer (NSCLC) before the first dose of trial treatment. However, subjects who received adjuvant or neoadjuvant therapy during an earlier stage of their disease, but evolved to stage IV, are eligible. Tyrosine kinase inhibitor (TKI) selected as first-line systemic treatment. Is participating in an interventional trial or medical need program.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Primary study group<br>Stage IV untreated NSCLC | Other: None - Common practice<br>* None - Common practice<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Study Outcome is Defined as the Systemic Treatment Choice. | Systemic treatment choices are defined as : Chemotherapy (chemo) Immunotherapy (IO) immuno combined therapies (IO+IO) IO+chemo IO+bevacizumab+chemo (IO+bev+chemo) best supportive care (BSC). There is no exposure in this study. | during visits 1 and 2, up to approximately 3 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Treatment choice